Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

Дата публикации: 14-06-2026 22:06:43

FOSTER CITY, Calif. & WILMINGTON, Del. – June 14, 2026 – Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)	0	18.81	22-06-2026
2	Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile	0	16.82	10-08-2026
3	Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1C	0	13.62	23-07-2026
4	Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy	0	12.6	21-07-2026
5	Novo Nordisk Provides Update on the ZEUS Phase 3 Trial of Ziltivekimab in People with ASCVD, CKD and Inflammation	0	12.26	31-07-2026
6	Novo Nordisk's Denecimig (Mim8) Demonstrated Positive Results in Long Term Safety and Efficacy in Phase 3 Hemophilia A FRONTIER Extension Study	0	15.61	11-07-2026
7	Efzimfotase Alfa Demonstrated Improvements in Bone Health in Treatment-Naïve Pediatric Patients with Hypophosphatasia in MULBERRY Phase III Trial	0	12.32	28-06-2026
8	Агидель: Ночь 20 дек, Чт	0	0	19-12-2018
9	Багаевская: День 18 дек, Вт	0	0	17-12-2018
10	Багаевская: Ночь 18 дек, Вт	0	0	17-12-2018

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.36. Источник: www.drugs.com.